✦ LIBER ✦

Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia

✍ Scribed by Keller-v.Amsberg, Gunhild ;Brümmendorf, Tim H

Book ID: 120310685
Publisher: Expert Reviews
Year: 2012
Tongue: English
Weight: 672 KB
Volume: 12
Category: Article
ISSN: 1473-7140
DOI: 10.1586/era.12.84

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bosutinib: a dual SRC/ABL kinase inhibit

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

✍ Keller, Gunhild; Schafhausen, Philippe; Brummendorf, Tim H 📂 Article 📅 2009 🏛 Expert Reviews 🌐 English ⚖ 321 KB

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Dasatinib, a Novel Abl-Src Kinase Inhibi

Dasatinib, a Novel Abl-Src Kinase Inhibitor, in the Management of Patients with Philadelphia Chromosome–Positive Leukemias

✍ Mughal, Tariq I. 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 105 KB

Efficacy and Safety of a Specific Inhibi

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

✍ Druker, Brian J.; Talpaz, Moshe; Resta, Debra J.; Peng, Bin; Buchdunger, Elisabe 📂 Article 📅 2001 🏛 Massachusetts Medical Society 🌐 English ⚖ 177 KB

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera

Outcome of allogeneic SCT in patients wi

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

✍ Oyekunle, Anthony; Zander, Axel R.; Binder, Mascha; Ayuk, Francis; Zabelina, Tat 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 229 KB